ArticleThe American journal of pathology1994
Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.
Article in The American journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Clinical significance of nm23 expression and chromosome 17 numerical aberrations in primary gastric cancer.Medical oncology (Northwood, London, England) · 2002Article
- Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation.Molecular pathology : MP · 2000Article
- Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma.The American journal of pathology · 1999Article
- Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?British journal of cancer · 1998Article
- Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer.The American journal of pathology · 1997Article
- DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH.Urological research · 1997Article
- Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.World journal of urology · 1997Review
- Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization.The American journal of pathology · 1996Article
- Numerical chromosome alterations in colorectal carcinomas detected by fluorescence in situ hybridization. Relationship to 17p and 18q allelic losses.Virchows Archiv : an international journal of pathology · 1996Article
- Prognostic significance of Bcl-2 in clinically localized prostate cancer.The American journal of pathology · 1996Article
- Chromosomal translocation t(X;18) in human synovial sarcomas analyzed by fluorescence in situ hybridization using paraffin-embedded tissue.The American journal of pathology · 1996Article
- Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization.The American journal of pathology · 1995Article
- c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.The American journal of pathology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To understand better the role of physical p53 deletion in bladder cancer, 106 formalin-fixed and 45 unfixed bladder tumors were examined using fluorescence in situ hybridization. Probes for centromere 17 and the p53 locus were hybridized simultaneously to interphase tumor cells to analyze p53 and chromosome 17 copy number on a cell by cell basis. 17p deletion was found in four of 43 pTa tumors, 18 of 43 pT1 tumors and 29 of 58 pT2-4 tumors (P = 0.0001). 17p deletion was also highly correlated with grade (P = 0.0001) and with p53 immunostaining (P = 0.0005). Chromosome 17 polysomy was associated with stage, grade, 17p deletions, and p53 immunostaining (P = 0.0001). The strong difference in centromere 17 copy number and 17p deletions between pTa and pT1 tumors supports a relevant biological distinction between pTa and pT1 tumors.
Indexed as
Identifiers
8160775PMC1887234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.